GLP-1 receptor agonists have fundamentally transformed the landscape of type 2 diabetes management and obesity treatment. At ADA 2027, this class of medications will be at the forefront of scientific discussion, with new clinical trial data, real-world evidence, and mechanistic insights anticipated from leading research groups worldwide.
Semaglutide, available in injectable and oral formulations, continues to generate landmark outcomes data across diabetes, obesity, cardiovascular disease, and chronic kidney disease. ADA 2027 will likely feature long-term follow-up data from major trials examining the broader cardiometabolic benefits of GLP-1-based therapies, including mortality reduction and heart failure outcomes.
The dual GLP-1 and GIP receptor agonist tirzepatide has demonstrated exceptional efficacy for both blood glucose lowering and weight reduction. ADA 2027 is expected to showcase new data on tirzepatide's effects in type 1 diabetes, non-alcoholic steatohepatitis, and sleep apnea, as well as comparative effectiveness data against other GLP-1 agents.
Beyond currently approved therapies, ADA 2027 will provide a window into next-generation incretin-based medicines. Oral GLP-1 agents with improved bioavailability, triple receptor agonists, and novel formulations designed for once-monthly dosing are all areas of active investigation likely to be featured at the 2027 congress.
June 2027
ADA 2027 Abstract Submission Guidelines
June 2027
